Agios Pharmaceuticals Announces Cancer Cell Publication of Research Illuminating Link between Cancer Metabolism and Epigenetics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the publication of a paper in Cancer Cell that illuminates the mechanism by which 2-hydroxyglutarate (2HG), and the mutations in the metabolic genes IDH1 and IDH2 that produce it, may be driving the growth of tumors in patients with acute myeloid leukemia (AML). This research was conducted as a collaboration between Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, the University of Pennsylvania and Agios.